Dexcom Inc

Dexcom Inc

DXCM

Get informed when a big investor buys or sells

+ Follow
Market Cap$28.45B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Dexcom IncDexcom Inc30.5-31%6.10.5

Earnings Call Q1 2026

April 30, 2026 - AI Summary

Strong results + raised profit/EBITDA margin outlook (core “good” news) - Q1’26 revenue: $1.19B (+15% YoY reported / +12% organic). - U.S. revenue: $832M (+11%); International revenue: $360M (+26% / +17% organic). - Gross margin: 63.5% of revenue, up sharply vs 57.5% in Q1’25; flat vs Q4 despite typical Q1 seasonality. - Profitability: Adjusted EBITDA $364.5M (36% of revenue) vs $230.4M (22.2%) in Q1’25; net income $216.3M (+75%). - Guidance reaffirmed / upgraded: Revenue guidance unchanged at $5.16B–$5.20B (+11% to +13%); increased non-GAAP operating margin to 23%–23.5% and adjusted EBITDA margin to 31%–31.5%.
Key growth driver: CGM adoption acceleration—especially U.S. Type 2 “non-insulin” - CEO emphasized category runway: ~30% CGM penetration into covered lives (i.e., 2/3 of covered lives not yet using CGM). - Share gains in Type 2 non-insulin attributed to broader access + product momentum + improved customer experience. - Major commercial reimbursement win: Prime Therapeutics to cover DexCom CGM for all people with diabetes (per CEO: beginning this summer). - Target/expectation: >7M Type 2 non-insulin lives with commercial coverage by end of 2026 (tracked as a meaningful catalyst toward broader U.S. growth).
Major catalyst in pipeline: CMS coverage for Type 2 non-insulin (timing uncertain) - Management reiterated CMS is the “largest single driver” (about half of Type 2 non-insulin lives are Medicare). - CEO expects CMS decision is “only a matter of time,” supported by ADA Standards of Care updates and accumulating real-world evidence. - No publication before ADA for the randomized controlled trial (RCT); full readout at ADA 2026 Scientific Sessions is expected to be the cornerstone evidence for payers. - Risk/uncertainty: CMS timing not guaranteed; competitor commentary suggested near-term possibility, but DexCom would not “call the month.”

Exclusive for Stockcircle Pro members

Sign upSign Up
$80.83

Target Price by Analysts

11.1% upsideDexcom Target Price DetailsTarget Price
$75.48

Current Fair Value

3.7% upside

Undervalued by 3.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$28.45 Billion
Enterprise Value$28.74 Billion
Dividend Yield$- (-)
Earnings per Share$2.14
Beta1.4
Outstanding Shares385,100,000

Return

Return on Equity31.47%ROE
Return on Assets14.03%
Return on Invested Capital23.44%

Valuation & Multiples

P/E Ratio30.52P/E Ratio
PEG34.19PEG
Price to Sales6.06Price to Sales
Price to Book Ratio10.4Price to Book Ratio
Enterprise Value to Revenue5.96
Enterprise Value to EBIT27.81
Enterprise Value to Net Income30
Total Debt to Enterprise0.05
Debt to Equity0.47Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 7, 2026
EPS Estimate
$0.47
Average shareholder expectation
Revenue Estimate
$1.17 B
Average shareholder expectation

Next Earnings Call

Expected Date
July 29, 2026
EPS Estimate
$0.60
Average shareholder expectation
Revenue Estimate
$1.29 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.9041▲ 19.84%
Total Calls3,694,896▼ 54.34%
Total Puts3,340,616▼ 41.51%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %94.01%▼ 0.70%
Total Invested$22.83B▼ 5.94%
Investors Holding999▲ 17.00%

ESG Score

No data

About Dexcom Inc

CEO: Kevin Sayer

Relevant Senate Committees

Finance

This committee controls taxation, trade, and entitlement spending, including Medicare and Medicaid. Decisions on Medicare reimbursement rates for medical devices are critical for Dexcom's revenue, and tax policy directly impacts its profitability.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA, which is the primary regulatory body for medical device approval. Decisions regarding product approvals, safety standards, and market access are fundamental to Dexcom's business.

Veterans' Affairs

This committee's funding decisions for the Department of Veterans Affairs directly impact government healthcare contractors and medical device manufacturers like Dexcom, whose products are often used by veterans and covered by VA healthcare.